Priveterra Acquisition Corp. II PMGM
- Market cap
- $97.5M
- P/E
- 75.9×
Follow PMGM
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 9.51 | 9.80 |
Analyst estimates 2023–2025 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 10.50 | 10.25 |
High Price
|
|||
| — | — | — | — | — | — | — | 5 | 5 | 5 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | 0 | 9 | 8 |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | 0 | — | — | 0 | 9 | 7 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (0.02) | 1.26 | 1.03 |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (0.15) | (0.22) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (0.15) | (0.22) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (0.01) | (3.12) | (2.41) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 6 | 7 | 7 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | 0 | (1) | (2) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | 0 | (1) | (2) |
FCF
|
|||
| — | — | — | — | — | — | — | 0 | 0 | (3) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 0 | — | 0 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | (21) | (17) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | (111.32%) | 6.18% | 4.58% |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | (0.08%) | (80.29%) | (37.32%) |
ROE
|
|||
Priveterra Acquisition Corp. II peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PPYA Papaya Growth Opportunity Corp. I | $97.3M | 0.0× | Compare |
| BLUAF BlueRiver Acquisition Corp. | $96.9M | 0.0× | Compare |
| CNDA Concord Acquisition Corp II | $95.8M | 69.4× | Compare |
| IXAQF IX Acquisition Corp. | $99.5M | 25.6× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IVCAF Libity | $95.3M | 0.0× | Compare |
| SPKL Spark I Acquisition Corporation | $100.4M | 0.0× | Compare |
| DSAQ Direct Selling Acquisition Corp. | $94.5M | 0.0× | Compare |
| TAVI Tavia Acquisition Corp. | $94.2M | — | Compare |
Priveterra Acquisition Corp. II (PMGM) key facts
- Priveterra Acquisition Corp. II (PMGM) is a Shell Companies company in the Financial sector, listed on Nasdaq.
- As of July 26, 2024, PMGM traded at $11.05, a market capitalization of $97.5 million.
- Return on equity was −37.3% and debt-to-equity 0.00.
Priveterra Acquisition Corp. II (PMGM) Latest News
3 May
Priveterra Acquisition Corp. II received a notice from Nasdaq regarding late filing of Annual Report on Form 10-K. The late filing of the Annual Report on Form 10-K may moderately influence the company's financial performance and market sentiment.
24 Jul
AEON Biopharma completes business combination with Priveterra Acquisition Corp., secures funding for clinical development of ABP-450. The completion of the business combination and funding arrangements are expected to significantly impact AEON Biopharma's future clinical development and market positioning.
21 Jul
Priveterra Acquisition Corp. completes business combination with AEON Biopharma, Inc., changing its name to AEON Biopharma, Inc. and expected to commence trading on NYSE on July 24, 2023. The completion of the business combination with AEON Biopharma, Inc. and the upcoming trading on NYSE are significant strategic moves that could alter Priveterra Acquisition Corp. II's trajectory and investor sentiment.
17 Jul
Priveterra Acquisition Corp. authorized to list on NYSE as AEON Biopharma, Inc. after business combination with AEON Biopharma, Inc. The authorization to list on NYSE and the upcoming business combination are significant moves that could alter the company's trajectory and investor sentiment.
11 Jul
Priveterra Acquisition Corp. to transfer to NYSE after business combination with AEON Biopharma, Inc. The transfer to NYSE and business combination with AEON Biopharma, Inc. are significant strategic moves that could fundamentally alter the company's trajectory and investor sentiment.
30 Jun
AEON Biopharma and Priveterra secure up to $125 million in funding for proposed business combination, including forward purchase agreements. The secured funding of up to $125 million is a significant move that could impact Priveterra's future trajectory and market performance.